Cargando…

(82) Effect of Suvorexant on COVID-19 Associated Delirium

Detalles Bibliográficos
Autores principales:	Nazeer, Sahana, Preud'homme, Xavier, Rivelli, Sarah, Hankey, Maria S., Kablinger, Anita S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646390/ http://dx.doi.org/10.1016/j.jaclp.2022.10.085

Ejemplares similares

Rapid effect of suvorexant and high-dose melatonin on COVID-19 associated delirium
por: Nazeer, Sahana, et al.
Publicado: (2023)

Suvorexant for the prevention of delirium: A meta-analysis
por: Xu, Shu, et al.
Publicado: (2020)

Refined Method of Lipofilling following DIEP Breast Reconstruction: 3D Analysis of Graft Survival
por: Nelissen, Xavier, et al.
Publicado: (2015)

PT653. Experience using suvorexant to treat delirium
por: Fujiwara, Kodo, et al.
Publicado: (2016)

Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant
por: Booka, Eisuke, et al.
Publicado: (2017)

Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting
por: Tamura, Kiyoshi, et al.
Publicado: (2018)

Proceedings: B and T cell membrane markers in human leukaemias and lymphomata.
por: Seligmann, M., et al.
Publicado: (1975)

Collision Cross Section Prediction with Molecular Fingerprint Using Machine Learning
por: Yang, Fan, et al.
Publicado: (2022)

Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer’s Disease: A Case-series Study
por: Hanazawa, Tomoki, et al.
Publicado: (2019)

Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial
por: Azuma, Kazunari, et al.
Publicado: (2018)

Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study
por: Ikeuchi, Shoya, et al.
Publicado: (2023)

Profile of suvorexant in the management of insomnia
por: Sutton, Eliza L
Publicado: (2015)

Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study
por: Shiotsuka, Junji, et al.
Publicado: (2022)

Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit
por: Azimaraghi, Omid, et al.
Publicado: (2020)

Suvorexant: a promising, novel treatment for insomnia
por: Lee-Iannotti, Joyce K, et al.
Publicado: (2016)

Distinct effects of IPSU and suvorexant on mouse sleep architecture
por: Hoyer, Daniel, et al.
Publicado: (2013)

Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study
por: Hatano, Masakazu, et al.
Publicado: (2018)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Is suvorexant a better choice than alternative hypnotics?
por: Kripke, Daniel F.
Publicado: (2015)

Suvorexant for insomnia in older adults: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2018)

Suvorexant Poisoning in a Patient With Cirrhosis and Renal Failure
por: Ito, Hiroshi, et al.
Publicado: (2021)

Inertness of Superoxide Dismutase Mimics Mn(II) Complexes Based on an Open-Chain Ligand, Bioactivity, and Detection in Intestinal Epithelial Cells
por: Schanne, Gabrielle, et al.
Publicado: (2022)

Suvorexant improves intractable nocturnal enuresis by altering sleep architecture
por: Matsumoto, Tohru
Publicado: (2021)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs
por: McGaughey, Georgia, et al.
Publicado: (2014)

Initial Presentation of OCD and Psychosis in an Adolescent during the COVID-19 Pandemic
por: Nazeer, Sahana, et al.
Publicado: (2022)

2420 Examining characteristics of placebo effects on trauma-related insomnia in a suvorexant trial
por: Uweh, Kimberly
Publicado: (2018)

PT654. Suvorexant induced restless legs syndrome; a case report
por: Ogihara, Tomomi, et al.
Publicado: (2016)

Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus
por: Toi, Norikazu, et al.
Publicado: (2018)

Quantification of Suvorexant in Human Urine Using a Validated HPTLC Bioanalytical Method
por: Alqarni, Mohammed H., et al.
Publicado: (2023)

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly
por: Vermeeren, Annemiek, et al.
Publicado: (2016)

PT666. Check an effeciency About the Suvorexant with Combining Other Sleep Promoting Medicines
por: Akira Iwanami, Toshiaka Tsuneoka, et al.
Publicado: (2016)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
por: Kale, Hrishikesh P., et al.
Publicado: (2021)

The mean age of gender dysphoria diagnosis is decreasing
por: Sun, Ching-Fang, et al.
Publicado: (2023)

COVID-19 Induced Brief Psychotic Disorder: A Case Report and Review of Literature
por: Bakre, Sulaimon, et al.
Publicado: (2022)

Kin relationships in cultural species of the marine realm: case study of a matrilineal social group of sperm whales off Mauritius island, Indian Ocean
por: Sarano, Francois, et al.
Publicado: (2021)

EXM 82.19
por: Battisti, S
Publicado: (1982)

CCM 82-19
Publicado: (1982)

Rubidium-82 PET/CT in COVID-19
por: van de Burgt, Alina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8023svtd0r50m0b07gdjtsha0s